Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246

Roma-Rodrigues, C., Fernandes, A. R. & Baptista, P. V. Exosome in tumour microenvironment: overview of the crosstalk between normal and cancer cells. BioMed Res. Int. 2014, 179486 (2014).

Kosaka, N., Yoshioka, Y., Fujita, Y. & Ochiya, T. Versatile roles of extracellular vesicles in cancer. J. Clin. Invest. 126, 1163–1172 (2016).

Jelonek, K., Widlak, P. & Pietrowska, M. The influence of ionizing radiation on exosome composition, secretion and intercellular communication. Protein Pept. Lett. 23, 656–663 (2016).

Eldh, M. et al Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. PLoS ONE 5, e15353 (2010).

Yu, X., Harris, S. L. & Levine, A. J. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 66, 4795–4801 (2006).

Lespagnol, A. et al. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differ. 15, 1723–1733 (2008).

Freed-Pastor, W. A. & Prives, C. Mutantp53: one name, many proteins. Genes Dev. 26, 1268–1286 (2012).

Muller, P. A. & Vousden, K. H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25, 304–317 (2014).

Robles, A. I., Jen, J. & Harris, C. C. Clinical outcomes of TP53 mutations in cancers. Cold Spring Harb. Perspect. Med. 6, a026294 (2016).

Rivlin, N., Brosh, R., Oren, M. & Rotter, V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2, 466–474 (2011).

Zhu, J. et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 525, 206–211 (2015).

Cooks, T. et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23, 634–646 (2013).

Kim, M. P., Zhang, Y. & Lozano, G. Mutant p53: multiple mechanisms define biologic activity in cancer. Front. Oncol. 5, 249 (2015).

Bossi, G. et al. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 25, 304–309 (2006).

Alexandrova, E. M. et al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature 523, 352–356 (2015).

Zhang, W. C. et al. Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. Nat. Commun. 7, 11702 (2016).

Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39–51 (2010).

Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 3, 23–35 (2003).

Erreni, M., Mantovani, A. & Allavena, P. Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron. 4, 141–154 (2011).

Zhang, Q. W. et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE 7, e50946 (2012).

Fabbri, M. et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA 109, E2110–E2116 (2012).

Neviani, P. & Fabbri, M. Exosomic microRNAs in the tumor microenvironment. Front. Med. 2, 47 (2015).

Baer, C. et al. Suppression of microRNA activity amplifies IFN-gamma-induced macrophage activation and promotes anti-tumour immunity. Nat. Cell. Biol. 18, 790–802 (2016).

Hao, N. B. et al. Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol. 2012, 948098 (2012).

Verma, M., Lam, T. K., Hebert, E. & Divi, R. L. Extracellular vesicles: potential applications in cancer diagnosis, prognosis, and epidemiology. BMC Clin. Pathol. 15, 6 (2015).

Pitt, J. M., Kroemer, G. & Zitvogel, L. Extracellular vesicles: masters of intercellular communication and potential clinical interventions. J. Clin. Invest. 126, 1139–1143 (2016).

Baietti, M. F. et al. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat. Cell. Biol. 14, 677–685 (2012).

Nishida-Aoki, N. & Ochiya, T. Interactions between cancer cells and normal cells via miRNAs in extracellular vesicles. Cell. Mol. Life Sci. 72, 1849–1861 (2015).

Ogata-Kawata, H. et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS ONE 9, e92921 (2014).

Stevanato, L., Thanabalasundaram, L., Vysokov, N. & Sinden, J. D. Investigation of content, stoichiometry and transfer of miRNA from human neural stem cell line derived exosomes. PLoS ONE 11, e0146353 (2016).

Zhang, Y. et al. Hypothalamic stem cells control ageing speed partly through exosomal miRNAs. Nature 548, 52–57 (2017).

Chan, C. W. et al. Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX1. Proc. Natl Acad. Sci. USA 106, 1936–1941 (2009).

McClellan, J. L. et al. Linking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1. Am. J. Physiol. 303, G1087–G1095 (2012).

Russo, A. et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol. 23, 7518–7528 (2005).

Lee, M. K. et al. Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. Cancer Cell 22, 751–764 (2012).

Vaughan, C. A. et al. Allele specific gain-of-function activity of p53 mutants in lung cancer cells. Biochem. Biophys. Res. Commun. 428, 6–10 (2012).

Chen, W. & Konkel, J. E. TGF-beta and ‘adaptive’ Foxp3(+) regulatory T cells. J. Mol. Cell Biol. 2, 30–36 (2010).

Shen, Z. et al. Higher intratumoral infiltrated Foxp3+Treg numbers and Foxp3+/CD8+ratio are associated with adverse prognosis in resectable gastric cancer. J. Cancer Res. Clin. Oncol. 136, 1585–1595 (2010).

Tiemessen, M. M. et al. CD4+CD25+Foxp3+regulatory T cells induce alternative activation of human monocytes/macrophages. Proc. Natl Acad. Sci. USA 104, 19446–19451 (2007).

Villarroya-Beltri, C. et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat. Commun. 4, 2980 (2013).

Brucher, B. L. & Jamall, I. S. Cell-cell communication in the tumor microenvironment, carcinogenesis, and anticancer treatment. Cell. Physiol. Biochem. 34, 213–243 (2014).

Chowdhury, R. et al. Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget 6, 715–731 (2015).

Costa-Silva, B. et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell. Biol. 17, 816–826 (2015).

Ekstrom, E. J. et al. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol. Cancer 13, 88 (2014).

Kalluri, R. The biology and function of exosomes in cancer. J. Clin. Invest. 126, 1208–1215 (2016).

Jackson, J. G. & Lozano, G. The mutant p53 mouse as a pre-clinical model. Oncogene 32, 4325–4330 (2013).

Cordani, M. et al. Mutant p53 proteins alter cancer cell secretome and tumour microenvironment: involvement in cancer invasion and metastasis. Cancer Lett. 376, 303–309 (2016).

Madar, S. et al. Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta. PLoS ONE 8, e61353 (2013).

Lujambio, A. et al. Non-cell-autonomous tumor suppression by p53. Cell 153, 449–460 (2013).

Trivedi, M., Talekar, M., Shah, P., Ouyang, Q. & Amiji, M. Modification of tumor cell exosome content by transfection with wt-p53 and microRNA-125b expressing plasmid DNA and its effect on macrophage polarization. Oncogenesis 5, e250 (2016).

Shimomura, A. et al. A novel combination of serum microRNAs for detecting breast cancer in the early stage. Cancer Sci. https://doi.org/10.1111/cas.12880 (2016).

Neerincx, M. et al. MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing. Oncogenesis 4, e170 (2015).

Kim, G. et al. Hsa-miR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancer. Lung Cancer 91, 15–22 (2016).

Zhang, Q. et al. p53-induced microRNA-1246 inhibits the cell growth of human hepatocellular carcinoma cells by targeting NFIB. Oncol. Rep. 33, 1335–1341 (2015).

Zhang, Y., Liao, J. M., Zeng, S. X. & Lu, H. p53 downregulates Down syndrome-associated DYRK1A through miR-1246. EMBO Rep. 12, 811–817 (2011).

Whiteside, T. L. Exosomes and tumor-mediated immune suppression. J. Clin. Invest. 126, 1216–1223 (2016).

van Rooij, E. & Kauppinen, S. Development of microRNA therapeutics is coming of age. EMBO Mol. Med. 6, 851–864 (2014).

Gyorgy, B., Hung, M. E., Breakefield, X. O. & Leonard, J. N. Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annu. Rev. Pharmacol. Toxicol. 55, 439–464 (2015).

Zawacka-Pankau, J. & Selivanova, G. Pharmacological reactivation of p53 as a strategy to treat cancer. J. Intern. Med. 277, 248–259 (2015).

Soragni, A. et al. A designed inhibitor of p53 aggregation rescues p53 tumor suppression in ovarian carcinomas. Cancer Cell. 29, 90–103 (2016).

De Palma, M. & Lewis, C. E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23, 277–286 (2013).

Gorgoulis, V. G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907–913 (2005).

Thery, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. Unit3(Chapter 3), 22 (2006).

Forshew, T. et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. 4, 136ra168 (2012).

Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).